Conflicting Views Between Epileptologists and General Neurologists Hinder Adoption of New Refractory Epilepsy Treatments EXTON, PA, July 08, 2024 (GLOBE NEWSWIRE) -- Chronic epilepsy is often well managed by neurologists, but a sizable proportion of adults with epilepsy continue to experience seizures at varying...

Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights EXTON, PA, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Millions of people worldwide are affected by Parkinson’s disease (PD), prompting the need for effective disease-modifying therapies (DMTs) to target this...

Neuronetrix publishes peer-reviewed paper validating the clinical application of ERP biomarkers for use in Alzheimer's disease LOUISVILLE, Ky., Nov. 18, 2015 (GLOBE NEWSWIRE) -- Neuronetrix announced today the publication of results from its multi-center clinical trial in a prestigious Alzheimer's journal. The report, "A...

Neuronetrix joins big pharma to sponsor conference on Clinical Trials for Alzheimer's Disease LOUISVILLE, Ky., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Neuronetrix announced today that it has joined pharma giants Lilly, Roche, Lundbeck, Janssen, and others to sponsor the 8th Annual Clinical Trials on...